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Background
Antiretroviral regimens (ART) with few changes due to
side effects or treatment failure are preferred. Therefore,
duration of treatment and persistence (defined as conti-
nuing therapy or not) are useful measures of success of
ART. We studied duration of ART in treatment-experi-
enced patients (TEP) and analyzed how a history of
non-adherence affects it.
Methods
In September 2009, we conducted a retrospective, obser-
vational study of adult TEP whose ART was switched
between 01/05/2008 and 30/04/2009. We used phar-
macy records to select all patients who switched an
ART containing darunavir, raltegravir, maraviroc, and/or
etravirine and patients who had switched regimens not
containing these drugs (1:1) on the same day. The pri-
mary endpoint was duration of treatment from inclusion
until the last refill, or until the first refill of a new regi-
men. Patients were classified as non-adherent if they
had collected less than 90% of the doses needed during
the year before inclusion. Control variables were viral
load (VL), CD4 count at inclusion, and time since first
ART regimen (tART). Persistence was estimated using
Kaplan-Meier plots. Groups were compared using the
log-rank test and a Cox regression model was adjusted
for control variables.
Results
We included 146 patients (66.4% men); mean age 45.4
years. Baseline clinical characteristics (median [IQR])
were VL = 50 (50-7331) copies/mL, CD4 count = 345
(184-540) cells/μL, tART = 10.0 (4.2-10.7) years.
Etravirine, maraviroc, and/or raltegravir were adminis-
tered to 45.9% of patients, and efavirenz to 21.9%.
Persistence (95% CI) at 6 and 12 months was 77.9%
(70.9%-84.9%) and 65.9% (55.5%-76.5%), respectively.
Mean duration of treatment was 342 (15) days. Non-
adherence was observed in 29.3% (21.2%-37.3%). Persis-
tence at 12 months for adherent and non-adherent
patients was 71.7% (58.1%-85.3%) vs 59.0% (32.2%-
84.8%), respectively (p = 0.342). There were no differ-
ences in persistence adjusted for control variables (HR,
0.774 [0.343-1.750]; p = 0.539).
After a median 281 days of follow-up, 24.7% (17.7-
31.6) had stopped or changed ART because of toxicity
(52.8%), treatment failure (19.4%), or simplification
(8.3%).
Discussion
Our results for persistence are similar to published data
for naïve patients and toxicity is also the main reason
for switching treatment. A history of non-adherence has
less effect on persistence than expected.
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